Literature DB >> 28978957

Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis.

Sarah Fischer1, Timo Rath1, Carol-Immanuel Geppert2, Bernhard Manger3, Georg Schett3, Markus F Neurath1, Raja Atreya1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28978957     DOI： 10.1038/ajg.2017.242

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  4 in total

1.  Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.

Authors:  Robert Hirten; Randy S Longman; Brian P Bosworth; Adam Steinlauf; Ellen Scherl
Journal:  Am J Gastroenterol       Date:  2015-12       Impact factor: 10.864

2.  Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

Authors:  Bruce E Sands; Richard Kozarek; Jack Spainhour; Charles F Barish; Scott Becker; Lawrence Goldberg; Seymour Katz; Ronald Goldblum; Rena Harrigan; Deborah Hilton; Stephen B Hanauer
Journal:  Inflamm Bowel Dis       Date:  2007-01       Impact factor: 5.325

3.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

4.  Long-term Efficacy of Vedolizumab for Ulcerative Colitis.

Authors:  Edward V Loftus; Jean-Frédéric Colombel; Brian G Feagan; Severine Vermeire; William J Sandborn; Bruce E Sands; Silvio Danese; Geert R D'Haens; Arthur Kaser; Remo Panaccione; David T Rubin; Ira Shafran; Megan McAuliffe; Arpeat Kaviya; Serap Sankoh; Reema Mody; Brihad Abhyankar; Michael Smyth
Journal:  J Crohns Colitis       Date:  2017-04-01       Impact factor: 9.071
  4 in total
  6 in total

Review 1.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

Review 2.  Recent advances and emerging therapies in the non-surgical management of ulcerative colitis.

Authors:  Jan Wehkamp; Eduard F Stange
Journal:  F1000Res       Date:  2018-08-07

Review 3.  Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor.

Authors:  Cristiano Pagnini; Theresa T Pizarro; Fabio Cominelli
Journal:  Front Pharmacol       Date:  2019-06-18       Impact factor: 5.810

Review 4.  Anti-integrin therapy for inflammatory bowel disease.

Authors:  Sung Chul Park; Yoon Tae Jeen
Journal:  World J Gastroenterol       Date:  2018-05-07       Impact factor: 5.742

Review 5.  Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.

Authors:  Christine Olbjørn; Jon Bergreen Rove; Jørgen Jahnsen
Journal:  Paediatr Drugs       Date:  2020-08       Impact factor: 3.022

Review 6.  A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.

Authors:  Hang Hock Shim; Pak Wo Chan; Sai Wei Chuah; Brian J Schwender; San Choon Kong; Khoon Lin Ling
Journal:  JGH Open       Date:  2018-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.